774800login-checkTwo-week direct-acting antiviral prophylaxis prevents hep C after kidney transplant |
By Elana Gotkine
Two-week direct-acting antiviral (DAA) prophylaxis prevents hepatitis C virus (HCV) infection in individuals without HCV viremia who received kidney transplant (KT) from donors with HCV viremia (HCV D+/R−), according to a study published online Nov. 28 in the Annals of Internal Medicine.
Niraj M. Desai, M.D., from the Johns Hopkins University School of Medicine in Baltimore, and colleagues examined the safety and efficacy of two-week DAA prophylaxis for HCV D+/R− KT in a small uncontrolled trial involving 10 patients. Read the article in Medical Xpress.
774800login-checkTwo-week direct-acting antiviral prophylaxis prevents hep C after kidney transplant |